

Larotrectinib in a NTRK-rearranged soft tissue sarcoma in the neoadjuvant setting: a case report.

Catherine Percy¹, Schubert Thomas¹, Christine Galant¹, Thomas Kirchgesner¹, and Filomena Mazzeo¹

¹Cliniques universitaires Saint-Luc

October 13, 2020

Abstract

NTRK gene-fusions are rare but can occur in diverse cancers. The NTRK inhibitor larotrectinib is newly approved by the FDA. This paper reports the first case of a man with a NTRK-rearranged soft tissue sarcoma treated with larotrectinib in the neoadjuvant setting, in Belgium, to avoid limb amputation.

Hosted file

Case report Catherine_soumission.pdf available at <https://authorea.com/users/366713/articles/486389-larotrectinib-in-a-ntrk-rearranged-soft-tissue-sarcoma-in-the-neoadjuvant-setting-a-case-report>



